<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590001</url>
  </required_header>
  <id_info>
    <org_study_id>CRD0593, CRD0594, CRD0595</org_study_id>
    <nct_id>NCT04590001</nct_id>
  </id_info>
  <brief_title>Effect of the MobiusHD® in Patients With Heart Failure</brief_title>
  <acronym>HF-FIM</acronym>
  <official_title>A Feasibility Study Exploring the Effect of the MobiusHD® in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Dynamics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Dynamics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, open-label clinical trial intended to evaluate the&#xD;
      safety and effectiveness of the MobiusHD® in patients with heart failure and reduced ejection&#xD;
      fraction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects presenting with Class II or III heart failure with a left ventricular ejection&#xD;
      fraction of ≤ 40% and NT-proBNP ≥ 400 will be considered for the study. Subjects who meet the&#xD;
      initial screening requirements will undergo non-invasive imaging of the carotid anatomy to&#xD;
      assess adequacy of the anatomy to allow placement of the MobiusHD device. Eligible subjects&#xD;
      will receive an implant placed in the internal carotid artery.&#xD;
&#xD;
      Following implantation of the device, subjects will be seen at 1 week, 1, 3, 6, 12, 18, and&#xD;
      24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in New York Heart Association Heart Failure Class</measure>
    <time_frame>24 months</time_frame>
    <description>Change in New York Heart Association Heart Failure Class between baseline and 3 months, 6 months, 12 months, 18 months and 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in NT-proBNP blood test levels</measure>
    <time_frame>24 months</time_frame>
    <description>Change in Amino-terminal prohormone of brain natriuretic peptide (NT-proBNP) between baseline and 3 months, 6 months, 12 months, 18 months, and 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QoL as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the EQ-5D Questionnaire.</measure>
    <time_frame>24 months</time_frame>
    <description>Change in QoL measures between baseline and 3 months, 6 months, 12 months, 18 months, and 24 months will be measured. The KCCQ is used to measure the effect of heart failure on quality of life with a lower score indicating a worsening quality of life. The EQ-5D Questionnaire is a general measure of overall health with a lower score indicating a better overall health perception.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 6MHW distance</measure>
    <time_frame>24 months</time_frame>
    <description>Change in 6MHW distance between baseline and 3 months, 6 months, 12 months, 18 months and 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cardiac function / structure</measure>
    <time_frame>24 months</time_frame>
    <description>Change will be evaluated using echocardiogram measured left ventricular ejection fraction, LV end diastolic volume, left atrial volume index, and severity of mitral regurgitation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of adverse events and serious adverse events, including serious adverse cardiovascular and neurological events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of cardiovascular mortality throughout the follow-up period will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Failure Hospitalizations</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of heart failure hospitalizations throughout the follow-up period will be reported.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>MobiusHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject enrolled in the study will undergo implantation of the MobiusHD device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MobiusHD</intervention_name>
    <description>The MobiusHD device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.</description>
    <arm_group_label>MobiusHD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or above&#xD;
&#xD;
          2. Currently NYHA Class II or III heart failure&#xD;
&#xD;
          3. Left ventricular ejection fraction ≤ 40%&#xD;
&#xD;
          4. NT-proBNP ≥ 400&#xD;
&#xD;
          5. Prescribed optimally-tolerated, stable, Guideline Directed Medical Therapy (GDMT) per&#xD;
             country specific guidelines for the treatment of heart failure for at least 4 weeks&#xD;
&#xD;
          6. Six-minute hall walk (6MHW) distance of ≥ 150 m AND ≤ 400 m&#xD;
&#xD;
          7. Deemed an acceptable candidate for the implant procedure by the investigator&#xD;
&#xD;
          8. Adequacy of the carotid anatomy for treatment with the MobiusHD implant based on&#xD;
             non-invasive carotid duplex and CTA/MRA imaging, and invasive carotid angiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or clinically suspected baroreflex failure or autonomic neuropathy&#xD;
&#xD;
          2. Currently implanted with a barostimulator device&#xD;
&#xD;
          3. Received cardiac resynchronization therapy (CRT) within six months of implantation&#xD;
&#xD;
          4. Received a CardioMEMS device within three months of the screening visit&#xD;
&#xD;
          5. History of any prior stroke with permanent neurologic defect or any prior intracranial&#xD;
             bleed or other serious brain injury&#xD;
&#xD;
          6. Body mass index &gt; 45&#xD;
&#xD;
          7. Serum estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73 m2&#xD;
&#xD;
          8. Presence of atherosclerotic plaque in the intended side for implantation as determined&#xD;
             by carotid duplex&#xD;
&#xD;
          9. Internal ICA lumen diameters &lt;4.5 mm or &gt;12.5 mm within the planned location of the&#xD;
             implant placement, or evidence of landing zone restrictions, such as inadequate&#xD;
             length, vessel tapering, and/or vessel curvature that would preclude safe placement of&#xD;
             the implant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>VP, Clinical</last_name>
    <phone>(949) 533-6101</phone>
    <email>bniksch@vasculardynamics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sr. Director, Clinical</last_name>
    <phone>(650) 208-1118</phone>
    <email>tshipman@vasculardynamics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsicore Ltd &quot;Israeli-Georgian Medical Research Clinic Helsicore&quot;</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Bekaia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tbilisi Heart and Vascular Center</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Shaburishvili</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CardioVascular Center - CVC Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine de Bruijn</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Mobius HD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

